Navigation Links
Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
Date:4/16/2008

Study Published in April 2008 Issue of Contraception

KENILWORTH, N.J., April 16 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced results of a recently completed study showing that non-compliance with combined hormonal contraceptives has noticeable effects on women's emotional well-being, prompted requests for physicians' advice and led to increased use of emergency contraception. Results were presented today in Madrid, Spain, and were published earlier this month in Contraception.

The cross-sectional, multi center study was designed to assess the self-described impact of noncompliant behavior among 26,250 current users, aged 18 to 49, of three combined hormonal contraceptive methods, the combined pill, the skin patch and NUVARING(R) (etonogestrel/ethinyl estradiol vaginal ring), the vaginal ring.

"The study included questions about attitudes and psychological impact of inconsistent use of the contraceptive method when confronted with noncompliant behavior, an issue that has been poorly characterized in previous studies," commented Dr Inaki Lete, Hospital Santiago Apostol, Vitoria-Gasteiz, Spain and lead investigator. "These considerations will help health-care professionals to empower women to increase compliance with the prescribed contraceptive regimens."

The study found that 71 percent of pill users, 32 percent of patch users and 21.6 percent of ring users reported noncompliant behavior ( p<0.0001 for all comparisons). Between 10 and 20 percent of women reported that noncompliant behavior with their current method negatively affected work activities and their relationship with their partner, and about 3 percent had missed days of work or school. A higher percentage of pill users reported that they were 'worried' or 'scared' (68.8 percent and 22.6 percent respectively) compared with women using the skin patch (61.7 percent and 19 percent) or the vaginal ring (58.3 percent and 16.4 percent) (p<0.0001).
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...ency of Poly-ICR as Vaccine Adjuvant, SAN DIEGO, ...euticals,Corporation (TSX: NVN) today presented po...prietary Toll-like Receptor 3 agonist, Poly IC-Pol...ss 2008 in Lyon, France.,Study results demonstrate...ng the Toll-like Receptor 3 (TLR3) pathway. Data s...
(Date:10/8/2008)... clinical improvement in patients with pulmonary ...atment options have limited benefit for this debil...ood vessel disease, -- Imatinib mesylate, avail...ancers, known to inhibit protein associated with P... imatinib mesylate in PAH in 2009 EAST HANOV...
(Date:10/7/2008)...wswire/ -- McLaren Health Care and its Great,Lakes...s leading medical,minds to share the latest work u...tinal cancer treatments. The October 11th symposiu...Laren,s Sukamal Saha, M.D., an,award-winning surgi... for,colorectal cancer has gained worldwide recogn...
(Date:10/7/2008)...ewswire/ -- The Texas Cardiac Arrhythmia,Institute...ected as one of,only a few sites in the nation to ...a new device to treat persistent atrial fibrillati... research center specializing in heart,rhythm diso...l Center and,Texas Cardiovascular Consultants., "...
Breaking Medicine Technology:Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds 26 Flu 916 1Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds 26 Flu 916 2Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds 26 Flu 916 3BIO key 28R 29 and Tiger IT Awarded a Follow on Contract for Nationwide Voter Citizen Registration in Bangladesh 1341 1BIO key 28R 29 and Tiger IT Awarded a Follow on Contract for Nationwide Voter Citizen Registration in Bangladesh 1341 2BIO key 28R 29 and Tiger IT Awarded a Follow on Contract for Nationwide Voter Citizen Registration in Bangladesh 1341 3BIO key 28R 29 and Tiger IT Awarded a Follow on Contract for Nationwide Voter Citizen Registration in Bangladesh 1341 4New study highlights stigma and stress of living with HIV AIDS in Serbia 6945 1New study highlights stigma and stress of living with HIV AIDS in Serbia 6945 2New study highlights stigma and stress of living with HIV AIDS in Serbia 6945 3UF botanists 3A Flowering plants evolved very quickly into 5 groups 1338 1UF botanists 3A Flowering plants evolved very quickly into 5 groups 1338 2UF botanists 3A Flowering plants evolved very quickly into 5 groups 1338 3
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...Health Minister on the prescription issue. Under t...cribe in Wales. The move has been widely criticize...tion. "GPC Wales welcomes the statement of the H...rse and pharmacist prescribing in Wales. Doctors a...
...ochrane Collaboration (International private organ...rom various clinical trials) reviewed data from ov... and treatment. // The researchers found that th...uenza were not found to be effective now, some dru...
...ths due to medical errors are on the rise. Medical...n given on the drug labels. Food and Drug Administ...ght section //thereby making it easy for the docto...fore they could assess a drug as completely safe f...
...the twilight zone between life and death help the .... Dr Hasan Alam, a trauma surgeon at Massachusett...tails of this method. //In this method the surgeon...patients and perform the surgery. After the compl...
Other Medicine News:Health News:New Rule Results In The Complete Makeover In The Field Of Drug Advertising 2
Flattened Blunt Tip, Angled; 13mm from angle to tip; 3mm "U" shape tip; overall length excluding hub 28mm; in stainless steel.
Set of Five, Long, with side port; all approximately 75mm in length; in Stainless Steel.
HYDRACLEAR is our brandname for a remarkable moisture rich element that lies throughout the interior and exterior of the ACUVUE ADVANCE Brand Contact Lenses creating a unique soft, silky feel.
The only solution for in-line digital measurement
Medicine Products: